Wellgistics Health Inc. SEC Filings

Wellgistics Health (WGRX) disclosed a Form 3 from director Howard Doss, an initial statement of beneficial ownership. The filing indicates no securities are beneficially owned by the reporting person as of the event date 10/02/2025.

The form was filed by one reporting person and includes a Power of Attorney (Exhibit 24.1). This is a routine ownership disclosure and does not reflect a transaction.

Wellgistics Health (WGRX) announced a non-binding letter of intent with DataVault to explore integrating PharmaChain, a manufacturer-to-patient blockchain-enabled smart contract solution, into Wellgistics’ technology and physical infrastructure for the prescription drug industry.

The contemplated collaboration would focus on digitizing prescription fulfillment workflows with a potential revenue-sharing arrangement, but economic and other material terms remain under negotiation and there is no assurance any agreement or revenues will result. The companies stated the contemplated solution does not involve tokens or digital assets. A joint press release was furnished as Exhibit 99.1.

Wellgistics Health, Inc. (WGRX) announced governance changes approved by written consent of holders representing approximately 55.5% of voting power. Effective October 1, 2025, the majority holders removed Rebecca Shanahan and Michael Peterson from the Board without cause under Delaware law. The consents delivered represented 49,825,505 shares of common stock.

Following the actions, the company disclosed the resignation of Donald Anderson (effective October 2, 2025) and appointed Donald Fell, Prashant Patel, Steven D. Lee, and Howard Doss to the Board on October 2, 2025. The Board named Mr. Patel President and assigned committee roles, including Mr. Doss as Audit Committee chair. The company reported 89,621,242 shares outstanding as of the October 1, 2025 record date, and identified three new directors as “independent” under applicable NASDAQ and SEC rules.

Wellgistics Health, Inc. (WGRX) reported a new insider status change: Director Donald Fell filed a Form 3 initial statement of beneficial ownership. The filing states that no securities are beneficially owned.

The event date is 10/02/2025, indicating the point at which the reporting obligation began. This is an administrative disclosure under Section 16 and does not reflect a transaction or change in the company’s capital.

Wellgistics Health, Inc. filed a Form 8-K under Item 7.01 (Regulation FD) to furnish a press release dated October 13, 2025 as Exhibit 99.1.

The company states the furnished information is not deemed “filed” for purposes of Section 18 of the Exchange Act and is not incorporated by reference. The press release contains forward-looking statements, and readers are directed to risk disclosures in the company’s SEC filings, including its Form S-1 declared effective on September 25, 2025.

Wellgistics Health, Inc. (WGRX) reported an initial insider ownership filing. A director filed a Form 3 with an event date of 10/02/2025, indicating no securities are beneficially owned.

The filing was made by one reporting person, and a Power of Attorney was included as Exhibit 24.1.

Wellgistics Health, Inc. reported the immediate removal of two directors from its board. The filing states that Rebecca Shanahan and Michael Peterson were removed as directors effective immediately. At the time of their removals, Ms. Shanahan served on the Ethics Committee and Mr. Peterson served as the chair of the Audit Committee. The notice appears as a concise disclosure of governance changes without additional explanation of reasons, replacements, or related corporate actions.

Wellgistics Health, Inc. (WGRX) is offering 7,142,862 shares of Common Stock at $0.70 per share, producing approximately $4,650,003 of proceeds before expenses with placement agent fees of $350,000. After the offering and assuming no warrants are exercised, the company expects 91,406,962 shares outstanding. The filing discloses a consolidated net loss of $39,103,367 for a reported period, with weighted average common shares of 56,863,720 and a net loss per share of $0.63 in one table. Pro forma and segment tables show other reported net losses (for example, $10,592,215 and $6,856,226 in separate schedules). The company reports an actual net tangible book value per share before the offering of $(0.47) and an offering price of $0.70, but the filing leaves some post-offering per-share calculations blank. The company completed the Wellgistics acquisition with cash consideration terms including a $10 million closing payment and issuance of a $17,500,000 note payable (amended terms), plus issuance of 3,999,335 restricted shares valued at $15,000,000 as equity consideration. A U.S. utility patent application titled "Method and Apparatus for Prescription Management" was filed July 26, 2022 and submitted September 26, 2023 to protect the company’s tech and hub platform.